INMB Quote, Financials, Valuation and Earnings

Citius Oncology has a net margin of -19478% compared to INmune Bio's net margin of --. INmune Bio's return on equity of -122.48% beat Citius Oncology's return on equity of --.

INmune Bio has a consensus price target of $7.65, signalling upside risk potential of 110.26%. On the other hand Citius Oncology has an analysts' consensus of $3.00 which suggests that it could grow by 91.08%. Given that INmune Bio has higher upside potential than Citius Oncology, analysts believe INmune Bio is more attractive than Citius Oncology.

INmune Bio has a beta of 1.336, which suggesting that the stock is 33.612% more volatile than S&P 500. In comparison Citius Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

INmune Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio pays -- of its earnings as a dividend. Citius Oncology pays out -- of its earnings as a dividend.

INmune Bio quarterly revenues are $50K, which are larger than Citius Oncology quarterly revenues of --. INmune Bio's net income of -$9.7M is lower than Citius Oncology's net income of -$7.7M. Notably, INmune Bio's price-to-earnings ratio is -- while Citius Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio is 1,061.01x versus -- for Citius Oncology. Usually stocks with elevated PS ratios are considered overvalued.

GlucoTrack has a net margin of -19478% compared to INmune Bio's net margin of --. INmune Bio's return on equity of -122.48% beat GlucoTrack's return on equity of --.

INmune Bio has a consensus price target of $7.65, signalling upside risk potential of 110.26%. On the other hand GlucoTrack has an analysts' consensus of -- which suggests that it could fall by --. Given that INmune Bio has higher upside potential than GlucoTrack, analysts believe INmune Bio is more attractive than GlucoTrack.

INmune Bio has a beta of 1.336, which suggesting that the stock is 33.612% more volatile than S&P 500. In comparison GlucoTrack has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.622%.

INmune Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlucoTrack offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio pays -- of its earnings as a dividend. GlucoTrack pays out -- of its earnings as a dividend.

INmune Bio quarterly revenues are $50K, which are larger than GlucoTrack quarterly revenues of --. INmune Bio's net income of -$9.7M is lower than GlucoTrack's net income of -$6.8M. Notably, INmune Bio's price-to-earnings ratio is -- while GlucoTrack's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio is 1,061.01x versus 6.23x for GlucoTrack. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -19478% compared to INmune Bio's net margin of -907.48%. INmune Bio's return on equity of -122.48% beat Moderna's return on equity of -29.23%.

INmune Bio has a consensus price target of $7.65, signalling upside risk potential of 110.26%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that INmune Bio has higher upside potential than Moderna, analysts believe INmune Bio is more attractive than Moderna.

INmune Bio has a beta of 1.336, which suggesting that the stock is 33.612% more volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

INmune Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

INmune Bio quarterly revenues are $50K, which are smaller than Moderna quarterly revenues of $107M. INmune Bio's net income of -$9.7M is higher than Moderna's net income of -$971M. Notably, INmune Bio's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio is 1,061.01x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -19478% compared to INmune Bio's net margin of -486.44%. INmune Bio's return on equity of -122.48% beat Nektar Therapeutics's return on equity of -201.73%.

INmune Bio has a consensus price target of $7.65, signalling upside risk potential of 110.26%. On the other hand Nektar Therapeutics has an analysts' consensus of $94.83 which suggests that it could grow by 292.85%. Given that Nektar Therapeutics has higher upside potential than INmune Bio, analysts believe Nektar Therapeutics is more attractive than INmune Bio.

INmune Bio has a beta of 1.336, which suggesting that the stock is 33.612% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.928%.

INmune Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

INmune Bio quarterly revenues are $50K, which are smaller than Nektar Therapeutics quarterly revenues of $10.5M. INmune Bio's net income of -$9.7M is higher than Nektar Therapeutics's net income of -$50.9M. Notably, INmune Bio's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio is 1,061.01x versus 3.87x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.